Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06236893 · ClinicalTrials.gov registry record · NA
Randomized, Double-Blind Placebo-Controlled Trial to Assess Overall User Experience of a Synbiotic Vaginal Suppository
A NA study, sponsored by Seed Health.
- Completed
- Registry status
- NA
- Development phase
- 200
- Enrollment target
NCT06236893: Completed NA study, sponsored by Seed Health.
NCT06236893 is a NA study that has completed, run by Seed Health. The registered enrollment target is 200 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06236893, a NA study, has completed, sponsored by Seed Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the impact of a personal care product on vaginal health in individuals with a self-reported history of vaginal discomforts such as malodor, bothersome discharge, itching, irritation, and dryness. The personal care product, VH-01 contains a prebiotic and three distinct strains of Lactobacillus crispatus, a microbe commonly found in healthy vaginal microbiomes. The study will be a randomized, placebo-controlled trial where the test product will be compared to a placebo in a 2:1 manner. Participants will be asked to complete online questionnaires and provide vaginal samples to assess microbial communities. The aims of this study are to assess: 1. The user experience and acceptability of VH-01 vaginal suppository vs. placebo. 2. Attitudes and perceptions of VH-01 vaginal suppository usage vs. placebo. 3. Health-related quality of life during the use of VH-01 vaginal suppository vs. placebo. 4. Changes in self-perceived vaginal discomforts during the use of VH-01 vaginal suppository vs. placebo.
Primary Outcome
Self-reported rate of product acceptance to support vaginal health through month 3.
Interventions
- OTHER VH-01 vaginal suppository tablet
- OTHER Placebo vaginal suppository tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-01-29 |
| Est. Completion | 2024-07-31 |
| Phase | NA |
What the finished NCT06236893 record still lists
NCT06236893 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 2 interventions - of which VH-01 vaginal suppository tablet is the first listed.
NCT06236893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06236893 about?
NCT06236893 is a clinical study titled "Randomized, Double-Blind Placebo-Controlled Trial to Assess Overall User Experience of a Synbiotic Vaginal Suppository". The purpose of this study is to assess the impact of a personal care product on vaginal health in individuals with a self-reported history of vaginal discomforts such as malodor, bothersome discharge, itching, irritation, and dryness. The personal care product, VH-01 contains a prebiotic and three d...
What is the current status of trial NCT06236893?
This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 2024-01-29. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT06236893?
The interventions under investigation include: VH-01 vaginal suppository tablet (OTHER), Placebo vaginal suppository tablet (OTHER).
Who is sponsoring clinical trial NCT06236893?
This trial is sponsored by Seed Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06236893's enrollment target sits among peer trials
200 506th of 2000 higher than 1,434 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI